For laboratory and educational research use only. Not medical advice.
Women's Peptide Research
Ask Vera
Home  /  Database  /  Cagrilintide
Weight & Metabolicphase_2_3

Cagrilintide

AM833
Weight & Metabolic
ASK VERA ABOUT THIS ↗BUY NOW ↗
Category
Weight & Metabolic
Evidence grade
B
PubMed records
109
Female-tagged
18
Sex-analysis
0
CAS
—
B
Evidence grade B, Phase 2/3 human trial evidence across 109 indexed studies (mixed-sex). How grades work →
Female evidence: Extrapolated
Cagrilintide: of 109 PubMed records, 18 are tagged as including female subjects and 0 carry a sex-analysis tag.Counts reflect PubMed records as of 2026-07-17. “Female” uses the Female MeSH filter and “sex-analysis” the Sex Factors MeSH filter, automated proxies pending manual study-level review. Methodology →

Overview

Cagrilintide is a long-acting synthetic analogue of amylin, a pancreatic hormone that works alongside insulin in glucose and appetite regulation. Its lipidated, C-terminally amidated structure gives it an extended profile that makes it a convenient research material for studies of amylin-pathway signaling.

In preclinical and cell-based models cagrilintide has been studied for its activity at amylin and calcitonin receptors and for its role in nutrient-sensing and energy-balance pathways, including its interactions with incretin signaling. It is also under clinical investigation for metabolic research and is frequently studied in combination with the GLP-1 analogue semaglutide in a pairing known as CagriSema; it remains investigational rather than an approved product.

What makes cagrilintide a notable entry for a metabolic research catalog is its focus on the amylin axis as a complement to incretin signaling. Whether these mechanisms translate to female physiology remains an open research question; our evidence review tracks how many of the underlying studies included women.

Summary

Cagrilintide is a long-acting amylin analog in clinical development for weight management, frequently studied combined with semaglutide (CagriSema). Its trials enroll many women, but it is investigational, not approved, and female-specific questions have not been separately analyzed.

Evidence in women

Menstrual cycle
Unstudied
No published analysis of menstrual cycle-phase effects.
Pregnancy & lactation
Contraindicated
Investigational weight-management agent; not for use in pregnancy. No lactation data.
Hormonal interactions
Unstudied
Delayed gastric emptying could in principle affect oral-drug absorption, but a contraceptive or hormonal interaction has not been characterized for cagrilintide specifically.
Perimenopause & menopause
No evidence
No perimenopausal or menopausal-specific analysis is established.
Sex differences
No evidence
Trials enrolled women, but female-specific effects and dosing have not been separately established; the compound remains investigational.

Mechanism

Amylin receptor agonist: promotes satiety and slows gastric emptying, complementary to GLP-1 signaling. Formulated for once-weekly subcutaneous dosing in trials.

Reported dosing & routes

◐

We don't give dosing or medical advice. The figures below describe what was used in published research, not a recommendation. Decide with your clinician.

Reported range (literature)Investigational once-weekly subcutaneous dosing in trials (literature figures, not advice).
Routessubcutaneous
Female-specific dosingNot established

Contraindications: investigational, not established in pregnancy

Side effects

Reported in the research literature. Sex-specific incidence has not been separately analysed in the available records.

nauseavomitinggastrointestinal effects

Cagrilintide reconstitution calculator

Enter this vial's amount, the bacteriostatic water you add, and a target amount to get the concentration and the U-100 syringe units to draw. Handling arithmetic for research use, not a dose recommendation.

Reconstitution

1
2
3

Draw for Cagrilintide

5
units on a U-100 insulin syringe
020406080100
U-100 insulin syringe — 1 mL = 100 units
That's 0.05 mL drawn to the 5-unit mark.
Concentration5 mg/mL (5,000 mcg/mL)
Volume to draw0.05 mL
Doses per vial40

Reference chart at 5 mg/mL

Target amountVolume (mL)U-100 units
100 mcg0.02 mL2
250 mcg0.05 mL5
500 mcg0.1 mL10
750 mcg0.15 mL15
1000 mcg0.2 mL20

Research-use arithmetic only. This tool converts a vial amount, diluent volume, and a target amount into a concentration and syringe draw for laboratory handling. It is not dosing guidance, a recommendation, or a claim of safety or efficacy, and it does not account for overfill, dead space, or peptide purity. Nothing here is medical advice. “U-100” means 100 units = 1 mL; confirm your syringe graduation before measuring. See the reconstitution & storage handbook for handling detail.

Frequently asked questions

Answers drawn only from Cagrilintide's research facts and, where reviewed, its sex-disaggregated evidence. Nothing here is medical advice, dosing, or a claim of safety or efficacy.

What is Cagrilintide?

Cagrilintide, also known as AM833, is a research compound in our weight metabolic category. Cagrilintide is a long-acting amylin analog in clinical development for weight management, frequently studied combined with semaglutide (CagriSema).

Is Cagrilintide studied in women?

Cagrilintide: of 109 PubMed records, 18 are tagged as including female subjects and 0 carry a sex-analysis tag. We grade this extrapolated: women appear in the record, but no study is tagged for a sex-specific analysis, so female-relevant conclusions are inferred from mixed or male data rather than measured in women. See our methodology.

Has Cagrilintide been studied during pregnancy or breastfeeding?

Contraindicated. Investigational weight-management agent; not for use in pregnancy. No lactation data. This is not a safety clearance or a recommendation. Vera, our research chat, deliberately hard-stops on pregnancy, breastfeeding, and trying-to-conceive questions rather than answer them.

What evidence grade does Cagrilintide have, and why?

Cagrilintide carries evidence grade B. Phase 2/3 human trial evidence across 109 indexed studies (mixed-sex).. Grades are derived from the research record, never hand-assigned; see how grades work.

Is there a female-specific dose for Cagrilintide?

No. A female-specific dose for Cagrilintide is not established, and this site does not provide dosing or medical advice. Any figures we show describe what published research used, not a recommendation. Decide anything about use with a qualified clinician.

How is Cagrilintide administered in research?

In the published literature, Cagrilintide is administered via subcutaneous. Reported dose ranges on the Dosing tab describe what studies used for laboratory research, not a protocol for people. We don't provide dosing.

What side effects have been reported for Cagrilintide?

Effects reported in the research literature include nausea, vomiting, gastrointestinal effects. Sex-specific incidence has not been separately analysed in the available records, so these are not broken out for women.

How should Cagrilintide be stored and handled?

Cagrilintide sold for research is supplied as a lyophilized (freeze-dried) powder. Lyophilized peptides are generally kept cold and dry, at roughly -20°C for longer-term storage and 2-8°C short-term, protected from light. Once reconstituted they are typically refrigerated and used within a short window, avoiding repeated freeze-thaw cycles. This is general laboratory handling for research use only, not a directive for human use. Always follow the handling and purity details on the product's Certificate of Analysis.

Where can I buy Cagrilintide for research?

For laboratory research use, Cagrilintide is available from our research-use partner, Aurevena Research. Applying code research15 takes 15% off. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.

Buy Cagrilintide at Aurevena Research
Research-use supplier: Cagrilintide is available from our research-use vendor for laboratory use. Code research15 for 15% off, applied automatically at checkout. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.
Buy now →

Related peptides

4X Blend (Methionine / Choline / Carnitine / Dexpanthenol)·
Multi-ingredient blend, its female evidence is reviewed per ingredient, not for the combination.
5-Amino-1MQD
5-Amino-1MQ: of 3 PubMed records, 2 are tagged as including female subjects and 0 carry a sex-analysis tag.
8X Blend (L-Carnitine / L-Arginine / Methionine / Inositol / Choline / B6 / B5 / B12)·
Multi-ingredient blend, its female evidence is reviewed per ingredient, not for the combination.
AdipotideD
Adipotide: of 4 PubMed records, 2 are tagged as including female subjects and 0 carry a sex-analysis tag.

Educational information for laboratory and research use only. Not medical advice, a recommendation, or a claim of safety or efficacy; no personal dosing. “Unstudied” means no qualifying study was found, not that a compound is safe or unsafe.